Patients' preferences regarding the timing of highly active antiretroviral therapy initiation for chronic asymptomatic HIV-1 infection.

Abstract:

OBJECTIVE:In patients with a chronic asymptomatic HIV-1 infection and >200 CD4+ T-cells/microl, the optimal timing of highly active antiretroviral therapy (HAART) initiation is unclear. It involves a trade-off between a potentially reduced risk of mortality, when started earlier in the course of infection, and an earlier exposure to pill burden and potential toxicities. We investigated patients' preferences for immediate HAART initiation relative to delaying HAART for 1 year. METHODS:Consecutive patients were asked for their preference during an interview. A hypothetical difference in 3-year mortality risk between both options was systematically varied between 0% and 10% to determine the threshold at which preference would switch to HAART initiation. RESULTS:About 30% of patients preferred HAART initiation even if the mortality risk would be equal for both options. Almost 25% always preferred delaying HAART even if this would result in a 10% greater mortality risk. Most treatment guidelines recommend delaying HAART >350 CD4+ T-cells/microl. However, at a risk difference between starting and delaying HAART that corresponds with this CD4+ T-cell count, about 50% would prefer to start HAART immediately. Most guidelines recommend starting HAART below 200 CD4+ T-cells/microl. However, at a risk difference between both options corresponding with this CD4+ T-cell count, about 40% preferred delaying HAART. CONCLUSIONS:We found large variation in patients' preferences. Some patients were more inclined to initiate HAART earlier than the recommended guidelines, whereas others were more inclined to delay HAART. These findings emphasize the need for shared decision-making when deciding on the most optimal timing of HAART initiation in chronic asymptomatic HIV-1 infection.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Locadia M,van Grieken RA,Prins JM,de Vries HJ,Sprangers MA,Nieuwkerk PT

subject

Has Abstract

pub_date

2006-01-01 00:00:00

pages

335-41

issue

3

eissn

1359-6535

issn

2040-2058

journal_volume

11

pub_type

杂志文章
  • Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19.

    abstract::Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 is highly inf...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3362

    authors: Xie X,Jiang Y,Zeng Y,Liu H

    更新日期:2020-06-04 00:00:00

  • A systematic review of a single-class maintenance strategy with nucleoside/nucleotide reverse transcriptase inhibitors in HIV/AIDS.

    abstract:BACKGROUND:Single-drug class regimens with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are generally not recommended as initial therapy because they are inferior compared with therapy with two NRTIs plus efavirenz. However, triple-NRTI combinations can be useful in specific circumstances such as in t...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,meta分析,评审

    doi:10.3851/IMP2726

    authors: Sprenger HG,Bierman WF,van der Werf TS,Gisolf EH,Richter C

    更新日期:2014-01-01 00:00:00

  • Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118).

    abstract:BACKGROUND:Amdoxovir (2,6-diaminopurine dioxolane; DAPD) is a nucleoside reverse transcriptase inhibitor (NRTI) of human immunodeficiency virus-1 (HIV-1) with activity against wild-type and NRTI-resistant viruses. METHODS:ACTG A5118 assessed the antiretroviral activity and safety of DAPD (300 mg orally, twice daily) v...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:

    authors: Gripshover BM,Ribaudo H,Santana J,Gerber JG,Campbell TB,Hogg E,Jarocki B,Hammer SM,Kuritzkes DR,A5118 Team.

    更新日期:2006-01-01 00:00:00

  • Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro.

    abstract:OBJECTIVE:The lipodystrophy syndrome is a major adverse effect of highly active antiretroviral therapy (HAART), associated with altered circulating levels and adipose tissue mRNA expression of proinflammatory cytokines interleukin-6 (IL-6) and tumour necrosis factor (TNF)alpha, and adiponectin. Proinflammatory cytokine...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Lagathu C,Bastard JP,Auclair M,Maachi M,Kornprobst M,Capeau J,Caron M

    更新日期:2004-12-01 00:00:00

  • External quality assessment of HLA-B*5701 reporting: an international multicentre survey.

    abstract:OBJECTIVES:HLA-B*5701 strongly predicts abacavir hypersensitivity (HSR), but implementation of effective routine screening into clinical practice requires testing be practical and accurate. We tested the proficiency of HLA-B*5701 typing among laboratories using sequence-specific primer PCR. DESIGN AND METHODS:DNA pane...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:

    authors: Hammond E,Almeida CA,Mamotte C,Nolan D,Phillips E,Schollaardt TA,Gill MJ,Angel JB,Neurath D,Li J,Giulivi T,McIntyre C,Koultchitski G,Wong B,Reis M,Rachlis A,Cole DE,Chew CB,Neifer S,Lalonde R,Roger M,Jeanneau A

    更新日期:2007-01-01 00:00:00

  • Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine.

    abstract::The aim of this study (the RESCUE trial) was to verify the effect of a shift from a lamivudine-containing to a didanosine-containing regimen on viral replication in HIV-1-infected subjects who had experienced prior treatment failure. Sixteen patients (didanosine-experienced in 14/16 cases) were consecutively enrolled:...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Rusconi S,La Seta Catamancio S,Citterio P,Bulgheroni E,Kurtagic S,Galazzi M,Croce F,Moroni M,Galli M

    更新日期:2001-03-01 00:00:00

  • Rapid semiquantitative real-time PCR for the detection of human cytomegalovirus UL97 mutations conferring ganciclovir resistance.

    abstract:BACKGROUND:The development of infections with ganciclovir (GCV)-resistant human cytomegalovirus (HCMV) remains a serious problem in recipients of stem cell or organ transplants. Nearly all GCV-resistant clinical isolates have mutations in the viral UL97 gene. The rapid detection of GCV-resistant HCMV infections is nece...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Göhring K,Mikeler E,Jahn G,Rohde F,Hamprecht K

    更新日期:2008-01-01 00:00:00

  • Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

    abstract:OBJECTIVE:To identify predictors of the virological response to antiretroviral therapy in patients in whom initial therapy has failed. METHODS:The Narval trial was designed to compare phenotyping, genotyping and standard of care for the choice of antiretroviral therapy in patients in whom a protease inhibitor (PI)-con...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Vray M,Meynard JL,Dalban C,Morand-Joubert L,Clavel F,Brun-Vézinet F,Peytavin G,Costagliola D,Girard PM,Narval Trial Group.

    更新日期:2003-10-01 00:00:00

  • Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV.

    abstract:BACKGROUND:Monocytes transmigrating to the brain play a central role in HIV neuropathology. We hypothesized that the continued existence of neurocognitive impairment (NCI) despite potent antiretroviral (ARV) therapy is mediated by the inability of such therapy to control this monocyte/macrophage reservoir. METHODS:Cro...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2411

    authors: Shikuma CM,Nakamoto B,Shiramizu B,Liang CY,DeGruttola V,Bennett K,Paul R,Kallianpur K,Chow D,Gavegnano C,Hurwitz SJ,Schinazi RF,Valcour VG

    更新日期:2012-01-01 00:00:00

  • Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.

    abstract:BACKGROUND:A genome-wide association study revealed an association between variants of the inosine triphosphatase (ITPA) gene and ribavirin (RBV)-induced anaemia. The aim of this study was to replicate this finding in an independent Japanese cohort and to define a method to allow pretreatment prediction of anaemia in c...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1796

    authors: Kurosaki M,Tanaka Y,Tanaka K,Suzuki Y,Hoshioka Y,Tamaki N,Kato T,Yasui Y,Hosokawa T,Ueda K,Tsuchiya K,Kuzuya T,Nakanishi H,Itakura J,Takahashi Y,Asahina Y,Matsuura K,Sugauchi F,Enomoto N,Nishida N,Tokunaga K,Miz

    更新日期:2011-01-01 00:00:00

  • In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis.

    abstract:BACKGROUND:In vitro studies have reported controversial effects of protease inhibitors (PIs) on mitochondrially driven apoptosis. Additionally, since PIs in the clinical setting are almost always given in combination with nucleoside analogues, which may have negative effects on mitochondrial DNA (mtDNA), the impact of ...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Miró O,Villarroya J,Garrabou G,López S,Rodríguez de la Concepción M,Pedrol E,Martínez E,Giralt M,Gatell JM,Cardellach F,Casademont J,Villarroya F

    更新日期:2005-01-01 00:00:00

  • Risk of cardiovascular disease associated with HCV and HBV coinfection among antiretroviral-treated HIV-infected individuals.

    abstract:BACKGROUND:The increased risk for cardiovascular disease (CVD) in HIV is well established. Despite high prevalence of viral hepatitis coinfection with HIV, there are few studies on the risk of CVD amongst antiretroviral therapy (ART)-treated coinfected patients. METHODS:Ontario HIV Treatment Network Cohort Study parti...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2724

    authors: Gillis J,Smieja M,Cescon A,Rourke SB,Burchell AN,Cooper C,Raboud JM,OHTN Cohort Study Group.

    更新日期:2014-01-01 00:00:00

  • Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.

    abstract:OBJECTIVES:To evaluate whether fuzzy operators can be usefully applied to the interpretation of genotypic HIV-1 drug resistance by experts, and to improve the prediction of salvage therapy outcome by adapting interpretation rules of genotypic resistance on the basis of their association with virological response data. ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:

    authors: De Luca A,Vendittelli M,Baldini F,Di Giambenedetto S,Trotta MP,Cingolani A,Bacarelli A,Gori C,Perno CF,Antinori A,Ulivi G

    更新日期:2004-08-01 00:00:00

  • HBV carrying drug-resistance mutations in chronically infected treatment-naive patients.

    abstract:BACKGROUND:Nucleoside/nucleotide analogue (NA) treatment causes selection pressure for HBV strains carrying mutations conferring NA resistance. Drug-resistance mutations occur in the reverse transcriptase (RT) region of the HBV polymerase gene and spontaneously arise during viral replication. These mutations can also a...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:10.3851/IMP2938

    authors: Gomes-Gouvêa MS,Ferreira AC,Teixeira R,Andrade JR,Ferreira AS,Barros LM,Rezende RE,Nastri AC,Leite AG,Piccoli LZ,Galvan J,Conde SR,Soares MC,Kliemann DA,Bertolini DA,Kunyoshi AS,Lyra AC,Oikawa MK,de Araújo LV,Carril

    更新日期:2015-01-01 00:00:00

  • Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice.

    abstract:BACKGROUND:Virological success (VS) and immunological reconstitution (IR) of antiretroviral-naive HIV-1-infected patients with pre-therapy viral load (VL) >500,000 copies/ml was assessed after 12 months of treatment according to initial drug-class regimens. METHODS:An observational multicentre retrospective study was ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3197

    authors: Santoro MM,Di Carlo D,Armenia D,Zaccarelli M,Pinnetti C,Colafigli M,Prati F,Boschi A,Antoni AMD,Lagi F,Sighinolfi L,Gervasoni C,Andreoni M,Antinori A,Mussini C,Perno CF,Borghi V,Sterrantino G

    更新日期:2018-01-01 00:00:00

  • Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools.

    abstract:BACKGROUND:Alterations in endogenous nucleotide pools as a result of HIV therapy with nucleoside and nucleotide reverse transcriptase inhibitors (N[t]RTIs) is a proposed mechanism for therapy-related adverse events and drug interactions resulting in treatment failure. In vitro studies were performed in order to underst...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Vela JE,Miller MD,Rhodes GR,Ray AS

    更新日期:2008-01-01 00:00:00

  • MicroRNAs: role and therapeutic targets in viral hepatitis.

    abstract::MicroRNAs regulate gene expression by binding to the 3'-untranslated region (UTR) of target messenger RNAs (mRNAs). The importance of microRNAs has been shown for several liver diseases, for example, viral hepatitis. MicroRNA-122 is highly abundant in the liver and is involved in the regulation of lipid metabolism. Mi...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2766

    authors: van der Ree MH,de Bruijne J,Kootstra NA,Jansen PL,Reesink HW

    更新日期:2014-01-01 00:00:00

  • Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.

    abstract::Clinical research has indicated that the use of nucleoside reverse transcriptase inhibitor (NRTI) and HIV protease inhibitor (PI) therapy is associated with a risk of long-term toxicity syndromes, and that the aetiopathogenesis of these adverse effects is independent of the antiretroviral effects of these drugs. In re...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Nolan D,John M,Mallal S

    更新日期:2001-09-01 00:00:00

  • The pathogenesis of liver disease in the setting of HIV-hepatitis B virus coinfection.

    abstract::There are many potential reasons for increased liver-related mortality in HIV-hepatitis B virus (HBV) coinfection compared with either infection alone. HIV infects multiple cells in the liver and might potentially alter the life cycle of HBV, although evidence to date is limited. Unique mutations in HBV have been defi...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Iser DM,Lewin SR

    更新日期:2009-01-01 00:00:00

  • The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.

    abstract:BACKGROUND:The nucleotide analogue, tenofovir, has been shown to lower plasma atazanavir levels in pharmacokinetic trials, an interaction that may be partly reversed by the addition of ritonavir, whereas plasma tenofovir levels are themselves raised when the drug is combined with lopinavir/ritonavir. OBJECTIVE:To inve...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Kruse G,Esser S,Stocker H,Breske A,Koerber A,Kopperman M,Wiehler H,Ross B,Möcklinghoff C,Hill A,Becker M,Kurowski M

    更新日期:2005-01-01 00:00:00

  • Prevalence of transmitted HIV-1 drug resistance among young adults attending HIV counselling and testing clinics in Kigali, Rwanda.

    abstract:BACKGROUND:Scaling-up antiretroviral therapy (ART) in resource-limited settings has raised concerns of emerging HIV drug resistance (DR) and its transmission to newly infected individuals. To assess the prevalence of transmitted drug resistance (TDR) in recently HIV-infected individuals, a WHO TDR threshold survey was ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2999

    authors: Mutagoma M,Ndahimana Jd,Kayirangwa E,Dahourou AG,Balisanga H,DeVos JR,McAlister D,Yang C,Bertagnolio S,Riedel DJ,Nsanzimana S

    更新日期:2016-01-01 00:00:00

  • In vitro susceptibility of geographically and temporally distinct Zika viruses to favipiravir and ribavirin.

    abstract:BACKGROUND:Zika virus, a previously neglected mosquito-borne virus, is prompting worldwide concern because of its connection with congenital defects, Guillain-Barré syndrome, meningoencephalitis and myelitis in infected individuals. However, no specific antiviral therapy is available at present. In this study, we inves...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3180

    authors: Baz M,Goyette N,Griffin BD,Kobinger GP,Boivin G

    更新日期:2017-01-01 00:00:00

  • In vitro inhibition of HIV-1 by Met-SDF-1beta alone or in combination with antiretroviral drugs.

    abstract::Compounds that can block the CXCR4 chemokine receptor are a promising new class of antiretroviral agents. In these experiments we studied the effect of a modified form of the native stromal cell-derived factor-1 (SDF-1), Met-SDF-1beta. The in vitro susceptibility of two different CXCR4-tropic HIV-1 strains was determi...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Rusconi S,Merrill DP,La Seta Catamancio S,Citterio P,Bulgheroni E,Croce F,Chou TC,Yang OO,Herrmann SH,Galli M,Hirsch MS

    更新日期:2000-09-01 00:00:00

  • HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy.

    abstract:BACKGROUND:In pregnant women taking antiretroviral treatment at conception treatment may be transiently stopped for safety concerns. Limited data are available on the consequences of such discontinuations. METHODS:We used data from a national study to compare different treatment pathways during pregnancy. Overall, 321...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Tamburrini E,Ravizza M,Floridia M,Tibaldi C,Alberico S,Anzidei G,Maccabruni A,Meloni A,Antoni AD,Mori F,Dalzero S,Conservan V,Pinnetti C,Ferrazzi E,Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy.

    更新日期:2008-01-01 00:00:00

  • Factors associated with HBV virological breakthrough.

    abstract:BACKGROUND:Little is known about non-adherence to HBV therapy. This study aimed to investigate the relationship between self-reported missed days of antiviral therapy and HBV virological breakthrough and factors associated with virological breakthrough. METHODS:A cross-sectional survey of 211 HBV patients receiving or...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:10.3851/IMP3087

    authors: Sheppard-Law S,Zablotska-Manos I,Kermeen M,Holdaway S,Lee A,Zekry A,Dore GJ,George J,Maher L

    更新日期:2017-01-01 00:00:00

  • HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?

    abstract:BACKGROUND:Clinical utilization of genotype resistance testing is evolving. We examined the extent to which HIV care providers requesting genotype resistance tests used the information appropriately and the impact of inappropriate utilization. METHODS:Data from a prospective cohort of HIV-infected patients (the HIV Ou...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Uy J,Brooks JT,Baker R,Hoffman M,Moorman A,Novak R,HOPS Investigators.

    更新日期:2007-01-01 00:00:00

  • Predicting antiretroviral drug resistance from the latest or the cumulative genotype.

    abstract:BACKGROUND:This study evaluates the added benefit when estimating antiretroviral drug resistance of combining all available resistance test results in a cumulative genotype relative to using the latest genotype alone. METHODS:The prevalence of resistance and genotypic sensitivity scores (GSS) predicted by the latest a...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1753

    authors: Garcia F,Alvarez M,Fox Z,Garcia-Diaz A,Guillot V,Johnson M,Chueca N,Phillips A,Hernández-Quero J,Geretti AM

    更新日期:2011-01-01 00:00:00

  • Antiviral activity of FNC, 2'-deoxy-2'-β-fluoro-4'-azidocytidine, against human and duck HBV replication.

    abstract:BACKGROUND:New drugs are needed to combat HBV infection. We investigated the anti-HBV activity of the deoxycytidine analogue FNC, which has anticancer activity and has been found to inhibit HCV replication. METHODS:In this study, a human hepatoma HepG2.2.15 cell culture system and duck HBV (DHBV) infection model were ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2094

    authors: Zheng L,Wang Q,Yang X,Guo X,Chen L,Tao L,Dong L,Li Y,An H,Yu X,Wang Q,Chang J

    更新日期:2012-01-01 00:00:00

  • Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results.

    abstract:BACKGROUND:In China, the clinical management of chronic hepatitis B (CHB) is complicated by the use of variousnucleoside/nucleotide analogue (NUC) regimens in treatment-naive patients, including NUCs with low genetic barriers to resistance, with/without add-on therapy and de novo NUC combinations. This longitudinal obs...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3851/IMP3205

    authors: Jia J,Tang H,Ning Q,Jiang J,Dou X,Zhang M,Zhang S,Shang J,Lu W,Ye Y,Wang X,Li M,Liu J,Bo Q,Tan W,EVOLVE Study Group.

    更新日期:2018-01-01 00:00:00

  • Targeting human papillomavirus genome replication for antiviral drug discovery.

    abstract::Human papillomavirus (HPV) infections are a major human health problem; they are the cause of recurrent benign warts and of several cancers of the anogenital tract and head and neck region. Although there are two prophylactic HPV vaccines that could, if used universally, prevent as many as two-thirds of HPV-induced ca...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2612

    authors: Archambault J,Melendy T

    更新日期:2013-01-01 00:00:00